Proceedings · Session S-689 · filed November 17, 2026

Research Funding & PolicySession paper

FDA Cannabinoid Data-Sharing Pacts: Six Expired, Two Extended to 2031, New York Joins

FDA records show six state cannabinoid information-sharing agreements now expired, Connecticut and South Carolina extended through 2031, and New York added as THC limits loom.

By Rebecca Stone3 min read622 words

Summary

  • Six of eight FDA state cannabinoid information-sharing agreements due to expire October 31, 2026 are now listed as expired.
  • Connecticut and South Carolina agreements were extended five years, through October 31, 2031.
  • New York's Office of Cannabis Management, signed by Executive Director John Kagia, joined the program through October 31, 2031.
  • Federal rules excluding plant-unproducible synthetic cannabinoids from hemp took effect the day of reporting; a 0.4 mg total-THC-per-container limit follows December 11.
  • The database now lists 15 cannabinoid-specific agreements running through 2031 and six with passed expiration dates.
FDA Records Show Six State Cannabinoid Information-Sharing Agreements Have Expired, Two Renewed Through 2031 and New Yor
FigureFDA Records Show Six State Cannabinoid Information-Sharing Agreements Have Expired, Two Renewed Through 2031 and New Yor — tiburi / pixabay

Six of the eight FDA information-sharing agreements with state cannabinoid regulators that were due to expire on October 31, 2026 now sit in the agency's public database as lapsed, while two have been extended five years and New York has joined the program, according to a review of FDA records published by The Marijuana Herald.

The expired listings cover six agencies: the California Department of Cannabis Control, the Kentucky Department for Public Health, the Ohio Division of Cannabis Control, the Oregon Liquor and Cannabis Commission, the Nevada Cannabis Compliance Board and the Vermont Cannabis Control Board. All six still carry the October 31, 2026 expiration date. The FDA's database gives no indication of whether extensions are pending or whether completed renewals have simply not yet appeared in the public record.

Which agreements were renewed?

The agreements with the Connecticut Department of Consumer Protection and the South Carolina Department of Agriculture were extended for another five years, pushing their expiration from October 31, 2026 to October 2031. The FDA also added a new agreement with the New York Office of Cannabis Management, signed by Executive Director John Kagia and running through October 31, 2031. The New York database entry was last updated October 19.

With New York added and the two extensions in place, the database now lists 15 cannabinoid-specific agreements with expiration dates of October 31, 2031, and six whose expiration dates have passed. Ohio holds a separate agreement, through its Department of Agriculture, that remains in effect.

The Marijuana Herald reported on October 16 that the FDA maintained 20 agreements allowing it to share confidential cannabinoid-related information with state and territorial regulators, eight of which were scheduled to expire at the end of October.

What do the agreements actually allow?

The arrangements operate under a federal regulatory framework known as 21 CFR 20.88. They authorize the FDA to give participating state agencies information that would otherwise be protected from public disclosure. That can include:

  • confidential business information
  • preliminary regulatory findings
  • personal privacy information
  • certain law enforcement records

Participating agencies must protect the information they receive and cannot distribute FDA records without the agency's permission. Agreements signed by an agency's highest-ranking official extend to employees operating under that official's authority.

The scope has limits worth noting for compliance planning. The cannabinoid-specific arrangements cover FDA-regulated hemp cannabinoid products and other products containing hemp-derived cannabinoids as ingredients. They do not grant blanket access to confidential information on all state-regulated marijuana products. The database also does not disclose what information has actually been exchanged, so the volume and substance of the sharing remain unknown.

Why does the timing matter?

The status of these agreements lands against a shifting federal hemp framework. Beginning on the day of the reporting, products containing cannabinoids that cannot be naturally produced by the marijuana plant are excluded from the federal definition of hemp. Most other changes to that definition — including a 0.4 milligram limit on total THC per container for final hemp-derived cannabinoid products — take effect December 11.

For state regulators and the companies they oversee, the practical consequence is uneven access. Regulators in Connecticut, South Carolina and New York retain formal confidential channels with the FDA through 2031, while their counterparts in six other states operate with agreements the record shows as expired, at a moment when federal enforcement definitions are changing under them.

The updated records show the FDA continuing to maintain and, with New York, expand formal channels for confidential communication with state cannabinoid regulators as the federal hemp rules tighten — with the December 11 THC-limit deadline the next concrete test of how those channels are used.

By Rebecca Stone

via themarijuanaherald.com (Source)

Filed under

  • fda-regulation
  • cannabinoid-data-sharing-agreements
  • hemp-regulatory-framework
  • 21-cfr-20-88
  • state-cannabis-regulators
Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Market editor covering regulation, policy and their impact on research and development at Hypothesis Wire.

274 articles

References

  1. Advocacy Group Pushes Congress for Federal Medical Cannabis Office
  2. DEA-Registered Lab Testing Mandate for Hemp Looms After Years of USDA Delays
  3. French Senate Backs Medical Marijuana Timetable Report
  4. FDA Shelves Priority Voucher Pilot After 22 Drug Vouchers
  5. FDA Proposes First Drug-to-Supplement Path That Could Reach CBD

« Previous articleNext article »